Academic Journals Database
Disseminating quality controlled scientific knowledge

Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives

ADD TO MY LIST
 
Author(s): Greg Hussack | Jamshid Tanha

Journal: Toxins
ISSN 2072-6651

Volume: 2;
Issue: 5;
Start page: 998;
Date: 2010;
Original page

Keywords: Clostridium difficile | Clostridium difficile-associated disease | toxin | antibody | single-domain antibody | neutralization | therapy

ABSTRACT
Therapeutic agents targeting bacterial virulence factors are gaining interest as non-antibiotic alternatives for the treatment of infectious diseases. Clostridium difficile is a Gram-positive pathogen that produces two primary virulence factors, enterotoxins A and B (TcdA and TcdB), which are responsible for Clostridium difficile-associated disease (CDAD) and are targets for CDAD therapy. Antibodies specific for TcdA and TcdB have been shown to effectively treat CDAD and prevent disease relapse in animal models and in humans. This review summarizes the various toxin-specific antibody formats and strategies under development, and discusses future directions for CDAD immunotherapy, including the use of engineered antibody fragments with robust biophysical properties for systemic and oral delivery.
     Get a faster system with an easy scan today!